© 2006 European Society of Cardiology
Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902
Department of Cardiology, University of Hull, Castle Hill Hospital Cottingham, Kingston-upon-Hull, HU15 5JQ, UK
* Corresponding author. Tel.: +44 1482 624086; fax: +44 1482 624085. E-mail address: a.p.coletta{at}hull.ac.uk
 |
Abstract |
|---|
This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the European Society of Cardiology heart failure meeting held in June 2006. All reports should be considered as preliminary data, as analyses may change in the final publication.
In a sub-group analysis of the TNT study, intensive treatment with high-dose atorvastatin significantly reduced hospitalisations for heart failure in patients with stable coronary heart disease, compared with low-dose atorvastatin; this benefit was most evident in patients with a history of heart failure at baseline. In a combined analysis of two studies of darbepoetin alfa, which included 475 patients, treatment increased and maintained haemoglobin levels and produced non-significant improvements in symptoms and morbidity in anaemic heart failure patients compared to placebo. In the FERRIC-HF study (n=35), intravenous iron sucrose therapy improved exercise capacity and symptom status in iron-deficient heart failure patients. In a combined analysis of two studies (n=186), the adenosine A1 receptor antagonist KW-3902 showed diuretic properties and appeared to enhance response to loop diuretics in heart failure patients hospitalised with fluid overload.
Key Words: TNT sub-study • Darbepoetin alfa • FERRIC-HF • KW-3902
Received July 7, 2006; Accepted July 11, 2006
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. G.F. Cleland, A. P. Coletta, A. Yassin, L. Buga, A. Torabi, and A. L. Clark Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADIT-CRT Eur J Heart Fail, December 1, 2009; 11(12): 1214 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, A. P. Coletta, A. Yassin, H. Hado, D. Cullington, A. T. Abdellah, and A. L. Clark Clinical trials update from the American College of Cardiology 2008: Carisma, Trends, meta-analysis of Cox-2 studies, Hat, on-Target, Hyvet, Accomplish, Momentum, Protect, Horizon-hf and Reverse Eur J Heart Fail, June 1, 2008; 10(6): 614 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cotter, M. Metra, O. Milo-Cotter, H. C. Dittrich, and M. Gheorghiade Fluid overload in acute heart failure -- Re-distribution and other mechanisms beyond fluid accumulation Eur J Heart Fail, February 1, 2008; 10(2): 165 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, A. P. Coletta, A. T. Abdellah, K. K. Witte, N. Hobson, and A. L. Clark Clinical trials update from Heart Rhythm 2007 and Heart Failure 2007: CARISMA, PREPARE, DAVID II, SAVE-PACE, PROTECT and AREA-IN-CHF Eur J Heart Fail, August 1, 2007; 9(8): 850 - 853. [Abstract] [Full Text] [PDF]
|
|